.png)
Heap discusses promising phase 3 results for zasocitinib, an oral TYK2 inhibitor, showcasing its efficacy and safety in psoriasis therapy.
Graham Heap, MBBS, PhD
Advertisement
Articles by Graham Heap, MBBS, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors
3
Timing, Severity, and Therapeutic Choice in Moderate to Severe HS
4
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
5